Similarly, bicyclol stimulated the expression of GSTA1, thereby reducing hepatic steatosis, suggesting that GSTA1 may be a good target for the discovery of drug candidates against MASLD. This evidence concerns the gene GSTA1 and metabolic dysfunction-associated steatotic liver disease.